8:00 am Registration & Morning Coffee

8:45 am Chair’s Opening Remarks

• Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research

9:00 am Industry Leader’s Briefing: Reviewing the Current Cell Therapy Landscape Across Asia

• James Li Co Founder & Chief Executive Officer, JW Therapeutics
• Cecilia Zhang Chief Scientific Officer, Biosyngen
• Christy Ma Chief Executive Officer, SCG Cell Therapy

9:30 am Commercial Case Study: Immunotherapy for Cancer Cure & Beyond – A Historical Mission

• Hao Shen Chief Scientific Officer, Fosun Kite Biotech

Advancing Next Generation Cell Therapies for Autoimmune Disorders

10:00 am Clinical Case Study: JW Therapeutics, Phase 1 Autoimmune Clinical Trial Data – Using CD19 CAR-T Therapy to Treat SLE Patients in China

• James Li Co Founder & Chief Executive Officer, JW Therapeutics

10:30 am Morning Refreshments & Speed Networking

11:30 am Advances and Clinical Applications of LNP Technologies in CAR-T Therapy

• Sawyer Xie Chief Executive Officer, DaRen Biotech

12:00 pm Preclinical Case Study: GF-CART01: Armoured CD19/CD20 Dual Targeting Non-Viral CAR T Therapy for B Cell Malignancy

• Ting-Wan Lin BD/PM Director, GenomeFrontier

12:30 pm Lunch & Networking

Evaluating & Improving CAR Design to Increase Anti-Tumor Efficacy for Improved Toxicity Profiles

1:30 pm Pre-Clinical Case Study: Strategy for Designing and Developing Dual- Targeting CAR-T Cell Therapies to Improve Safety for Enhanced Clinical Outcomes

• Maxwell Wang Founder & Chief Executive Officer, Skye Med

2:00 pm Preclinical Case Study: Advancements in Vd2 Gamma Delta T Cell Therapy for In Vivo Activation and Allogeneic Treatments

• Kok Fei Chan Research Fellow, Olivia Newton-John Cancer Research Institute

2:30 pm Navigating Clinical Trials for CAR-T Cell Therapy: Regional and Global Considerations

• Xuan-Hung Nguyen Chief Scientific Officer, VINMEC Hi Tech Center

3:00 pm Afternoon Refreshments & Poster Session

3:30 pm Signposting Regulatory Guidelines for Cell Therapy Development in the Asia-Pacific Region to Expedite Market Entry

• Sudipto Bari Assistant Director & Head of Translational Services & Regulatory Management, Advanced Cell Therapy and Research Institute, Singapore
• Danny Soon Chief Executive Officer, Consortium for Clinical Research and Innovation Singapore

4:15 pm Enhancing Therapeutic Impact: Integrating Co-stimulatory Signalling in TCR-T Therapies

• Wendell Yang Founder & President, Imgen BioSciences

4:45 pm Chair’s Closing Remarks

• Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research